2015
Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK. Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology. Neurotherapeutics 2015, 12: 151-169. PMID: 25384682, PMCID: PMC4322066, DOI: 10.1007/s13311-014-0310-1.Peer-Reviewed Original ResearchConceptsOutcome measuresNeurological disordersDisease-specific outcome measuresClinical trial measuresAssessment of dysfunctionAutonomic system functionMotor functionNervous systemRelated disordersDisordersDisease areasAmerican SocietyDrug developmentDysfunctionTrial measuresTerms of cognitionNeurologyAssessment developmentSystem functionAnnual MeetingNeurologistsSymptomsNeurotherapeutics
2000
Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans
Coulie B, Szarka L, Camilleri M, Burton D, McKinzie S, Stambler N, Cedarbaum J. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000, 119: 41-50. PMID: 10889153, DOI: 10.1053/gast.2000.8553.Peer-Reviewed Original ResearchConceptsNeurotrophic factorStool frequencyColonic transitR-metHuBDNFHealthy subjectsBrain-derived neurotrophic factorHuman brain-derived neurotrophic factorHuman gut motilityOverall colonic transitPassage of stoolRecombinant human brain-derived neurotrophic factorGastrointestinal motor functionSmall bowel transitInjection site reactionsWeeks of treatmentNeurotrophic factor 3Neurotrophin administrationBowel transitRandomized studyGut motilityColonic emptyingSite reactionsMotor functionConstipationHealthy people
1991
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Cedarbaum J, Olanow CW. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease. Neurology 1991, 41: 1567-70. PMID: 1922797, DOI: 10.1212/wnl.41.10.1567.Peer-Reviewed Original ResearchConceptsAdvanced Parkinson's diseaseDopamine sulfateParkinson's diseaseDopamine sulfate levelsLevodopa/carbidopaTime of transplantationPeak plasma concentrationAvailability of dopamineVentricular cerebrospinal fluidSulfate levelsClinical improvementMotor fluctuationsOmmaya reservoirSingle doseExogenous levodopaParkinsonian brainMotor functionPlasma concentrationsLateral ventricleCerebrospinal fluidAdrenal medullaLevodopaPatientsDiseaseDopamine
1989
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. Journal Of Neurology Neurosurgery & Psychiatry 1989, 52: 207. PMID: 2649640, PMCID: PMC1032507, DOI: 10.1136/jnnp.52.2.207.Peer-Reviewed Original ResearchConceptsStandard Sinemet 25/100Sinemet 25/100Sinemet CR4Controlled-release levodopa/carbidopaDouble-blind crossover comparisonDaily medication dosesDouble-blind partMean interdose intervalLevodopa/carbidopaAntiparkinson effectMedication dosesInterdose intervalSevere dyskinesiaCrossover comparisonCrossover trialParkinsonian patientsTherapeutic responseMedication administrationMotor functionAntiparkinsonian agentsParkinson's diseaseOpen treatmentMotor responsePatientsMotor performance